close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Brenus Pharma

News headline image
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 2026
From Brenus Pharma
Via Business Wire
News headline image
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients
From Brenus Pharma
Via Business Wire
News headline image
Brenus Pharma Expands Its Global Scientific Advisory Board With Us Immuno-Oncology Expert Prof. Olivera J. Finn
From Brenus Pharma
Via Business Wire
News headline image
Brenus Pharma Announces First Patients Dosed in its First-in-Human Trial Evaluating STC-1010, a Next-Generation Immunotherapy
From Brenus Pharma
Via Business Wire
News headline image
Brenus Pharma and InSphero Have Developed 3D Tumor Spheroids Mimicking in vivo Human Colorectal Cancer Conditions and Confirming STC-1010’s Efficacy
From Brenus Pharma
Via Business Wire
News headline image
AACR 2025: Brenus Pharma Presents Late-breaking Preclinical Data on its “off-the-shelf” Next-generation Vaccine-based Immunotherapy Candidate, STC-1010, Now Moving to Clinic
From Brenus Pharma
Via Business Wire
News headline image
Brenus Pharma Publishes Promising Proof of Concept Results of their Therapeutic Platform in the Scientific Frontiers in Oncology Journal. (1)
From Brenus Pharma
Via Business Wire
News headline image
Brenus Pharma Raises $25 Million to Accelerate Clinical Trials of Its Precision Cancer Vaccines.
From Brenus Pharma
Via Business Wire
News headline image
Brenus Pharma Wins French Tech Saint-Etienne Lyon's BIG Start-up of the Year Award
From Brenus Pharma
Via Business Wire
News headline image
Brenus Pharma graduates from the Creative Destruction Lab’s 2023/2024 Global Cancer Stream, in partnership with North American Universities.
From Brenus Pharma
Via Business Wire
News headline image
ASCO 2024: Brenus Pharma Presented “BreAK-CRC” First-in-human (FIH) Phase I/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC
From Brenus Pharma
Via Business Wire
News headline image
AACR 2024: Brenus Pharma Unveils Promising and Robust Pre-clinical Efficacy Extrapolating Human Conditions with STC-1010
From Brenus Pharma
Via Business Wire
News headline image
Brenus Pharma Wins the "Biotech" Trophy at the Prestigious Healthtech 2024 Awards Ceremony, Organized by France Biotech
From Brenus Pharma
Via Business Wire
News headline image
Brenus Pharma, Winner of the Call for Proposals "Innovations in Biotherapies and Bioproduction for France 2030", Receives €5 Million for Its Anticancer Vaccine Immunotherapy
From Brenus Pharma
Via Business Wire
News headline image
Brenus Pharma Joins the Paris Saclay Cancer Cluster (PSCC) to Collaborate at the Heart of Innovation in Oncology
From Brenus Pharma
Via Business Wire
News headline image
Brenus Pharma unveils promising pre-clinical results extrapolating human conditions in major international congresses.
From Brenus Pharma
Via Business Wire
News headline image
Brenus Pharma announces its international Scientific Committee
From Brenus Pharma
Via Business Wire
News headline image
Brenus Pharma Unveils Groundbreaking Preclinical Results For STC-10101, a Promising New Drug Candidate Targeting Colorectal Cancer & Solid Tumors
From Brenus Pharma
Via Business Wire
News headline image
French Blood Establishment (EFS) & Brenus Pharma Partner for the GMP Production of STC-1010, an Innovative Therapy Against Colorectal Cancer
From Brenus Pharma
Via Business Wire
News headline image
Brenus Pharma Announces its Strategic Committee Supporting & Ensuring Its Value-creating Strategic Plan
From Brenus Pharma
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today